Bruker Corporation (NASDAQ:BRKR) Stock Has Average Price Target of $59.43

by · The Markets Daily

Bruker Corporation (NASDAQ:BRKR – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the fourteen ratings firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, six have given a hold recommendation, five have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $60.57.

Several brokerages have recently weighed in on BRKR. JPMorgan Chase & Co. cut shares of Bruker from an “overweight” rating to a “neutral” rating and set a $60.00 price target for the company. in a research report on Wednesday, October 14th. Weiss Ratings reissued a “sell (d+)” rating on shares of Bruker in a report on Monday, August 31st. UBS Group initiated coverage on shares of Bruker in a report on Wednesday, September 9th. They set a “neutral” rating and a $65.00 price objective on the stock. Guggenheim boosted their price objective on shares of Bruker from $70.00 to $72.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Finally, Stifel Nicolaus set a $50.00 target price on Bruker in a report on Wednesday, August 5th.

Read Our Latest Research Report on Bruker

Bruker News Roundup

Here are the key news stories impacting Bruker this week:

  • Positive Sentiment: Bruker reported quarterly earnings of $0.56 per share, ahead of the $0.42 consensus, and revenue of $874 million versus estimates of $865 million. Revenue grew 1.6% year over year. Bruker Q3 Earnings and Revenues Surpass Estimates
  • Positive Sentiment: Analysts raised their targets: Leerink Partners lifted its target to $85 and maintained an Outperform rating, while Citigroup raised its target to $64 but kept a Neutral rating. Leerink Partners rating Citigroup rating
  • Positive Sentiment: Management cited margin expansion, strong bookings and returning U.S. academic demand; coverage also noted the company’s aim for double-digit EPS growth in 2027. Q3 earnings call highlights
  • Neutral Sentiment: Bruker completed a reorganization effective July 1, 2026, intended to streamline its structure, and updated segment reporting. The change may affect how investors compare business results across periods. Bruker completes reorganization and updates segment reporting
  • Negative Sentiment: Full-year revenue guidance of $3.52 billion–$3.56 billion put the top end at consensus, while adjusted EPS guidance of $2.10–$2.15 straddled the $2.12 estimate—solid, but not a clear upward revision. Coverage also highlighted a substantial goodwill charge, which may have weighed on investors’ assessment of the results. 2026 revenue outlook Q3 earnings and goodwill charge

Bruker Stock Performance

Shares of Bruker stock opened at $58.06 on Tuesday. The firm has a market cap of $8.85 billion, a P/E ratio of -52.78, a P/E/G ratio of 1.95 and a beta of 1.26. The company has a current ratio of 1.84, a quick ratio of 0.92 and a debt-to-equity ratio of 0.74. Bruker has a 12 month low of $32.37 and a 12 month high of $68.98. The stock’s fifty day moving average price is $58.97 and its 200-day moving average price is $50.53.

Bruker (NASDAQ:BRKR – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The medical research company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.42 by $0.14. Bruker had a positive return on equity of 13.76% and a negative net margin of 3.82%. The firm had revenue of $874.00 million during the quarter, compared to the consensus estimate of $865.16 million. During the same period in the previous year, the company posted $0.45 earnings per share. The firm’s quarterly revenue was up 1.6% on a year-over-year basis. On average, equities research analysts expect that Bruker will post 2.12 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st were issued a $0.05 dividend. The ex-dividend date was Monday, September 21st. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. Bruker’s dividend payout ratio (DPR) is currently -28.57%.

Insider Activity at Bruker

In other news, VP Mark Munch sold 2,000 shares of the business’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $52.87, for a total value of $105,740.00. Following the completion of the transaction, the vice president directly owned 134,806 shares of the company’s stock, valued at approximately $7,127,193.22. The trade was a 1.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 27.20% of the company’s stock.

Hedge Funds Weigh In On Bruker

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Global Retirement Partners LLC purchased a new stake in shares of Bruker during the second quarter valued at $38,000. Provenance Wealth Advisors LLC purchased a new position in Bruker in the 3rd quarter worth $52,000. Root Financial Partners LLC purchased a new position in Bruker in the 3rd quarter worth $57,000. Essential Partners LLC acquired a new stake in Bruker during the 1st quarter worth about $36,000. Finally, FNY Investment Advisers LLC acquired a new stake in Bruker during the 2nd quarter worth about $60,000. Hedge funds and other institutional investors own 79.52% of the company’s stock.

About Bruker

(Get Free Report)

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, molecules and biological processes. Its technologies support research, discovery and quality control in fields including life sciences, pharmaceutical development, chemical analysis, materials science, environmental testing and clinical research.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, infrared and Raman spectroscopy instruments, X-ray analysis equipment, microscopy and nanoanalysis systems, and preclinical imaging technologies.

Recommended Stories